All In Biotech

NDA 020246 · Pfizer

Depo-Provera

Medroxyprogesterone Acetate · Injection

Priority review

Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Oct 29, 1992

Approved uses

5

Original approval plus efficacy supplements

Registered trials

183

47 Phase 3, 16 recruiting

FAERS reports

32,474

27,392 serious, 486 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LOSS OF BONE MINERAL DENSITY • Women who use Depo-Provera Contraceptive Injection (Depo-Provera CI) may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible [see Warnings and Precautions (5.1) ] . • It is unknown if use of Depo-Provera CI during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life [see Warnings and Precautions (5.1) ] . • Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Indications and Usage (1) and Warnings and Precautions (5.1) ] . WARNING: LOSS OF BONE MINERAL DENSITY See full prescribing information for complete boxed warning . • Women who use Depo-Provera Contraceptive Injection...

What it is approved for

From the label in effect Aug 25, 2026.

Depo-Provera CI is indicated for use by females of reproductive potential to prevent pregnancy. Depo-Provera CI is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use: The use of Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. (1, 5.1) Limitations of Use : The use of Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ].

Mechanism: Depo-Provera CI (medroxyprogesterone acetate [MPA]) inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 4, 2020 Supplement 62 · Efficacy LetterLabelReview
  • Dec 4, 2020 Supplement 60 · Efficacy LetterLabel
  • Jul 28, 2011 Supplement 35 · Efficacy LabelLetter
  • Oct 15, 2010 Supplement 36 · Efficacy LetterLabel
  • Oct 29, 1992 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
1 products under this application
  • DEPO-PROVERA · MEDROXYPROGESTERONE ACETATE 150MG/ML · INJECTABLE, INJECTION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Medroxyprogesterone" as an intervention, any sponsor and status, largest first.

All 183 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • meningioma12,292
  • breast cancer female3,020
  • breast cancer1,857
  • drug ineffective922
  • headache780
  • nausea777
  • pain699
  • weight increased697
  • depression652
  • unintended pregnancy647
  • meningioma benign637
  • off label use607

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,555
20051,470
20061,242
2007463
2008433
2009850
20102,477
20111,191
2012807
2013495
2014570
2015756
2016856
2017505
2018463
2019711
2020573
2021463
2022759
2023742
2024919
20252,674
202611,499

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Depo-Provera (Medroxyprogesterone Acetate)

2024 spending

$10K

Beneficiaries

95

178 claims

Per beneficiary

$106

$56.81 per unit

View as table
YearSpending
2020$297,222
2021$14,262
2022$7,834
2023$10,484
2024$10,112

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,618 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.